Shares of Natco Pharma, on Monday, rose 4 per cent to Rs 935 on the BSE in intra-day trade after the company received emergency use approval for Baricitinib tablets for Covid-19 treatment.
“The company has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir is used for treatment of COVID-19 positive patients,” Natco Phamra said in exchange filing.
Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across
“The company has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir is used for treatment of COVID-19 positive patients,” Natco Phamra said in exchange filing.
Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across